Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen Acquires Majority Stake in Enzyme Provider Blirt

NEW YORK – Qiagen said on Wednesday that it has acquired a 96 percent stake in Blirt, a Gdansk, Poland-based manufacturer of recombinant enzymes for the life science industry.

Blirt develops, makes, and commercializes standardized and customized enzymes, other proteins, and molecular biology reagents. In particular, Qiagen noted, some of its products are critical to the life science industry and manufacturers of diagnostic kits, especially for COVID-19.

"The addition of Blirt to Qiagen brings highly complementary capabilities that will create additional growth prospects for our enzymes and reagents business," Thomas Schweins, senior VP and head of Qiagen's Life Sciences business area, said in a statement. "Blirt will also widen our geographic presence, add new sales channels, strengthen our production and R&D capacities, and safeguard our supply chains."

Financial terms of the transaction were not disclosed. Qiagen said it intends to obtain full ownership of Blirt by the second quarter of 2022. The acquisition will not have any material impact on Qiagen's financial outlook for 2022.

Blirt was founded in Gdansk in 1994, employs around 90 people, and generated 2021 sales of less than $10 million, Qiagen said.

The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.